MedTrace Logo

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

NCT07303465 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-24

No results posted yet for this study

Summary

This is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.

Conditions

  • KRAS G12D Mutations
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG

RNK08954

RNK08954 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Sponsors & Collaborators

  • Ranok Therapeutics (Hangzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • ShuKui Qing, MD · Nanjing Tianyinshan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-14
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07303465 on ClinicalTrials.gov